Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial] (2023)
- Authors:
- USP affiliated authors: CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; GUIMARÃES, FRANCISCO SILVEIRA - FMRP ; ZUARDI, ANTONIO WALDO - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP
- Unidade: FMRP
- DOI: 10.47626/1516-4446-2023-0047
- Subjects: CANABINOIDES; CANNABIS; ALUCINOGÊNICOS
- Language: Inglês
- Imprenta:
- Source:
- Título: Brazilian Journal of Psychiatry
- ISSN: 1516-4446
- Volume/Número/Paginação/Ano: v. 45, n. 3, p. 201-202, 2023
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
CRIPPA, José Alexandre de Souza et al. Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial]. Brazilian Journal of Psychiatry. São Paulo: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.47626/1516-4446-2023-0047. Acesso em: 12 fev. 2026. , 2023 -
APA
Crippa, J. A. de S., Guimarães, F. S., Zuardi, A. W., & Hallak, J. E. C. (2023). Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial]. Brazilian Journal of Psychiatry. São Paulo: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.47626/1516-4446-2023-0047 -
NLM
Crippa JA de S, Guimarães FS, Zuardi AW, Hallak JEC. Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial] [Internet]. Brazilian Journal of Psychiatry. 2023 ; 45( 3): 201-202.[citado 2026 fev. 12 ] Available from: https://doi.org/10.47626/1516-4446-2023-0047 -
Vancouver
Crippa JA de S, Guimarães FS, Zuardi AW, Hallak JEC. Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial] [Internet]. Brazilian Journal of Psychiatry. 2023 ; 45( 3): 201-202.[citado 2026 fev. 12 ] Available from: https://doi.org/10.47626/1516-4446-2023-0047 - Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning?
- Effects of minocycline on regional cerebral blood flow in schizophrenia
- Canabidiol: possíveis aplicacões terapêuticas em psicopatologias
- Cannabidiol, a cannabis sativa constituent, as an antipsycholic drug
- Possible therapeutic uses of cannabidiol in anxiety disorders and schizophrenia
- A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
- Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder
- Cannabidiol and neuroprotection: evidence from preclinical studies
- Cannabidiol displays proteomic similarities to antipsychotics in cuprizone-exposed human oligodendrocytic cell line MO3.13
- Marijuana, feijoada and the debate on drug legalization
Informações sobre o DOI: 10.47626/1516-4446-2023-0047 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003199340.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
